Published in Br J Cancer on December 01, 1993
A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry (1985) 2.72
Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer (1988) 1.77
The labelling index of human and mouse tumours assessed by bromodeoxyuridine staining in vitro and in vivo and flow cytometry. Cytometry (1985) 1.71
The cellular proliferation kinetics of animal tumors. Cancer Res (1970) 1.42
In vitro and in vivo labelling of animal tumours with tritiated thymidine. Cell Tissue Kinet (1973) 1.36
Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Br J Cancer (1992) 1.24
Immunohistochemical detection of proliferating cells in vivo. J Histochem Cytochem (1987) 1.22
Breast carcinoma cell kinetics, morphology, stage, and host characteristics. A thymidine labeling study. Lab Invest (1986) 1.20
Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine: intratumour sampling variations. Radiother Oncol (1988) 1.12
Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer (1989) 1.08
Labelling index of human squamous cell carcinomas. Comparison of in vivo and in vitro labelling methods. Cell Tissue Kinet (1979) 0.99
Double labeling with iodo- and bromodeoxyuridine for cell kinetics studies. J Histochem Cytochem (1989) 0.98
The effect of prolonged hypoxia on growth and viability of Chinese hamster cells. Int J Radiat Oncol Biol Phys (1977) 0.95
Cell kinetics of human tumors by in vitro bromodeoxyuridine labeling. J Histochem Cytochem (1989) 0.93
Tracer dose and availability time of thymidine and bromodeoxyuridine: application of bromodeoxyuridine in cell kinetic studies. Cell Tissue Kinet (1990) 0.90
Cell cycle kinetics of aerated, hypoxic and re-aerated cells in vitro using flow cytometric determination of cellular DNA and incorporated bromodeoxyuridine. Cell Tissue Kinet (1985) 0.87
Beta-fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res (1993) 0.87
Short-term variation in labeling index as a predictor of radiotherapy response in human oral cavity carcinoma. Int J Radiat Oncol Biol Phys (1984) 0.86
S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine. Int J Cancer (1986) 0.86
Measuring potential doubling times of murine tumors using flow cytometry. Cytometry (1991) 0.85
Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents. Cancer Res (1992) 0.83
Double labelling of tissue combining tritiated thymidine autoradiography with immunodetection of bromodeoxyuridine: the autoradiographic significance of inhibition of thymidine incorporation into DNA by bromodeoxyuridine given simultaneously. Cell Tissue Kinet (1989) 0.83
Cell proliferation in human tumour xenografts: measurement using antibody labelling against bromodeoxyuridine and Ki-67. Cell Prolif (1991) 0.81
Labelling index of gynaecological tumours assessed by bromodeoxyuridine staining in vitro using flow cytometry and histochemistry. Int J Radiat Biol (1989) 0.80
The cell cycle of glial cells grown in vitro: an immunocytochemical method of analysis. J Histochem Cytochem (1992) 0.80
Cell kinetic analysis of mixed populations using three-color fluorescence flow cytometry. Cytometry (1991) 0.80
Critical Appraisal of In Situ Cell Kinetic Measurements as Response Predictors in Human Tumors. Semin Radiat Oncol (1993) 0.79
Cell Proliferation Measurements by Bromodeoxyuridine or Thymidine Incorporation: Clinical Correlates. Semin Radiat Oncol (1993) 0.79
Flow cytometric analysis of experimental parameters for the immunofluorescent labeling of BrdUrd in various tumour cell lines. Histochemistry (1989) 0.78
Measuring cell proliferation by relative movement. I. Introduction and in vitro studies. Cell Prolif (1991) 0.77
Proliferative changes in two murine tumours in response to single or fractionated doses of X-rays. Cell Prolif (1992) 0.77
A new method for studying cell cycle characteristics in ANLL using double-labeling with BrdU and 3HTdr. Leuk Res (1987) 0.77
Application of antibodies to intermediate filament proteins as tissue-specific probes in the flow cytometric analysis of complex tumors. Anal Quant Cytol Histol (1986) 0.77
A two emulsion autoradiographic technique and the discrimination of the three different types of labelling after double labelling with 3H- and 14C-thymidine. Cell Tissue Kinet (1976) 0.76
A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry (1985) 2.72
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol (1997) 2.23
Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys (1997) 1.83
Demonstration of radiosensitization of hypoxic cells in solid tumours by metronidazole. Br J Radiol (1974) 1.77
Leisure-time physical activity but not work-related physical activity is associated with decreased plasma viscosity. Results from a large population sample. Circulation (1997) 1.57
Association between rheology and components of lipoproteins in human blood. Results from the MONICA project. Circulation (1992) 1.54
Can measurements of potential doubling time (Tpot) be compared between laboratories? A quality control study. Cytometry (1995) 1.47
Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer (1988) 1.44
Increased circulating levels of basement-membrane components in patients with abdominal aortic aneurysms--a pilot study. Eur J Vasc Endovasc Surg (2011) 1.43
The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report. Int J Radiat Oncol Biol Phys (1990) 1.37
Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem (2000) 1.34
The use of rodent tumors in experimental cancer therapy. Conclusions and recommendations from an international workshop. Cancer Res (1985) 1.33
DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer (2000) 1.31
Inhibitory effects of 13-cis-retinoic acid on human sebaceous glands. Arch Dermatol Res (1980) 1.22
Hypoxia in head and neck cancer: how much, how important? Head Neck (2005) 1.20
Single-agent chemotherapy of a solid murine tumor assayed by growth delay and cell survival. Cancer Res (1980) 1.16
Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine: intratumour sampling variations. Radiother Oncol (1988) 1.12
Adhesion of soluble fibronectin, laminin, and collagen type IV to intraocular lens materials. J Cataract Refract Surg (1999) 1.09
Biological properties and response to x-rays of first-generation transplants of spontaneous mammary carcinomas in C3H mice. Int J Radiat Biol Relat Stud Phys Chem Med (1975) 1.09
Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia (2011) 1.08
The incidence of lung metastases in C3H mice after treatment of implanted solid tumours with x-rays or surgery. Br J Cancer (1974) 1.05
Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer (2002) 1.00
Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk of liver and biliary tract cancers in Western Europeans. Ann Oncol (2012) 1.00
The clinical status of Tpot as a predictor? Or why no tempest in the Tpot! Int J Radiat Oncol Biol Phys (1995) 0.99
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer (1998) 0.99
What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation? Radiother Oncol (1985) 0.99
Analysis of growth delay data: potential pitfalls. Br J Cancer Suppl (1980) 0.96
Quantification of patient to patient variation of skin erythema developing as a response to radiotherapy. Radiother Oncol (1994) 0.95
Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br J Cancer (2012) 0.95
Defective repair of DNA double-strand breaks and chromosome damage in fibroblasts from a radiosensitive leukemia patient. Cancer Res (1995) 0.95
Modification of stromal radiosensitivity by misonidazole and WR-2721. Br J Radiol (1983) 0.95
A dose-response analysis of ethylnitrosourea-induced recessive specific-locus mutations in treated spermatogonia of the mouse. Mutat Res (1990) 0.94
Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol (2013) 0.94
Seasonal variations of rheological and hemostatic parameters and acute-phase reactants in young, healthy subjects. Arterioscler Thromb Vasc Biol (1997) 0.94
Plasma viscosity and the risk of coronary heart disease: results from the MONICA-Augsburg Cohort Study, 1984 to 1992. Arterioscler Thromb Vasc Biol (1998) 0.93
Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res (1990) 0.93
Optimum fractionation in X-ray treatment of C3H mouse mammary tumours. Br J Radiol (1974) 0.93
Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors. Radiother Oncol (1993) 0.92
Chronic myeloproliferative disorders (CMPD). Pathol Res Pract (1984) 0.92
Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br J Cancer (2009) 0.92
Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections. Cancer Res (1987) 0.92
Split dose recovery of a mouse tumour and its stroma during fractionated irradiation. Br J Radiol (1982) 0.91
Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients. Cancer Res (1988) 0.91
Fractionation with x rays and neutrons in mice: response of skin and C 3 H mammary tumours. Br J Radiol (1972) 0.91
Rapid repopulation in radiotherapy: a debate on mechanism. Accelerated repopulation in tumours and normal tissues. Radiother Oncol (1991) 0.91
The effect of radiation on G2 blocks, cyclin B expression and cdc2 expression in human squamous carcinoma cell lines with different radiosensitivities. Radiother Oncol (1994) 0.90
Letter: A rapid method for the determination of tumour RBE. Br J Radiol (1974) 0.90
Low predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following radiotherapy for breast cancer. Int J Radiat Biol (1998) 0.90
Combination therapy of a solid murine tumor with cyclophosphamide and radiation: the effects of time, dose and assay method. Int J Radiat Oncol Biol Phys (1979) 0.90
Tumour cell repopulation during fractionated radiotherapy: correlation between flow cytometric and radiobiological data in three murine tumours. Eur J Cancer (1991) 0.90
Consumption of fish and meats and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Oncol (2013) 0.90
Diffusion limited hypoxia estimated by vascular image analysis: comparison with pimonidazole staining in human tumors. Radiother Oncol (2000) 0.89
Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol (1982) 0.89
Proliferation equivalent of 'accelerated repopulation' in mouse oral mucosa. Int J Radiat Biol (1994) 0.89
Radiation-induced impairment of osseous healing: quantitative studies using a standard drilling defect in rat femur. Radiat Res (1995) 0.89
Fractionation response and repair kinetics of radiation-induced heart failure in the rat. Radiother Oncol (1992) 0.88
Radiosensitization by cisplatin of RIF1 tumour cells in vitro. Int J Radiat Biol Relat Stud Phys Chem Med (1986) 0.88
Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides. Cancer Chemother Pharmacol (1991) 0.88
The effects of combined bleomycin and irradiation on a solid murine tumor. Int J Radiat Oncol Biol Phys (1979) 0.87
Cell cycle kinetics of aerated, hypoxic and re-aerated cells in vitro using flow cytometric determination of cellular DNA and incorporated bromodeoxyuridine. Cell Tissue Kinet (1985) 0.87
Accelerated repopulation of mouse tongue epithelium during fractionated irradiations or following single doses. Radiother Oncol (1990) 0.87
The radiosensitivity of malignant melanomas part I: experimental studies. Int J Radiat Oncol Biol Phys (1981) 0.87
Cell loss from several types of solid murine tumour: comparison of 125I-iododeoxyuridine and tritiated thymidine methods. Cell Tissue Kinet (1977) 0.87
Geographical variations in plasma viscosity and relation to coronary event rates. Lancet (1994) 0.86
Potential of radiation-induced chromosome aberrations to predict radiosensitivity in human tumour cells. Int J Radiat Biol (1999) 0.86
Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer (2012) 0.85
Lack of cytosolic and transmembrane domains of type XIII collagen results in progressive myopathy. Am J Pathol (2001) 0.85
Assessment of bone marrow histology in the malignant lymphomas (non-Hodgkin's): correlation with clinical factors for diagnosis, prognosis, classification and staging. Br J Haematol (1982) 0.84
Fluorescent markers of hypoxic cells: a comparison of two compounds on three cell lines. Br J Radiol (1985) 0.84
Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution. Cancer Chemother Pharmacol (1991) 0.84
The radiosensitivity of malignant melanomas part II: clinical studies. Int J Radiat Oncol Biol Phys (1981) 0.84
A bioassay for cyclophosphamide in blood, lung and tumour. Br J Cancer (1984) 0.83
Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Res (1994) 0.83
Radiation response of the mouse tongue epithelium. Br J Cancer Suppl (1986) 0.83
Management of the hernial sac in inguinal hernia repair. Br J Surg (2010) 0.82
Radiosensitization in vitro by cis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40). Radiother Oncol (1987) 0.82
Fluorescent markers for hypoxic cells. A study of novel heterocyclic compounds that undergo bio-reductive binding. Biochem Pharmacol (1991) 0.82
Vascular architecture of experimental tumours--influence of tumour volume and transplantation site. Int J Radiat Biol (1991) 0.82
Intrinsic radiosensitivity and chromosome aberration analysis using fluorescence in situ hybridization in cells of two human tumor cell lines. Radiat Res (1994) 0.82
Association between plasma viscosity and blood pressure. Results from the MONICA-project Augsburg. Am J Hypertens (1991) 0.82
Type IV collagen as a tumour marker for colorectal liver metastases. Eur J Surg Oncol (2011) 0.81
Online measurement of oxygen consumption by goat bone marrow stromal cells in a combined cell-seeding and proliferation perfusion bioreactor. J Biomed Mater Res A (2006) 0.81
Increased radiation tolerance of mouse tongue epithelium after local conditioning. Int J Radiat Biol (1992) 0.81
Detection of radiation-induced chromosome aberrations using fluorescence in situ hybridization in drug-induced premature chromosome condensations of tumour cell lines with different radiosensitivities. Int J Radiat Biol (1997) 0.81
Use of fluorescence in situ hybridization to measure chromosome aberrations as a predictor of radiosensitivity in human tumour cells. Int J Radiat Biol (1994) 0.80
A new intraperitoneal tumor model in the rat. Cancer Chemother Pharmacol (1990) 0.80
Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. Cancer Chemother Pharmacol (2007) 0.80
Dietary intake of acrylamide and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Ann Oncol (2013) 0.80
Effects of hypoxia, pH, and growth stage on cell killing in Chinese hamster V79 cells in vitro by activated cyclophosphamide. Cancer Res (1985) 0.80
Stromal damage as a complication in the interpretation of tumour growth delay. Eur J Cancer Clin Oncol (1983) 0.80
Radiation-induced DNA damage and repair in radiosensitive and radioresistant human tumour cells measured by field inversion gel electrophoresis. Int J Radiat Biol (1993) 0.80
Complete exon-intron organization and chromosomal location of the gene for mouse type XIII collagen (col13a1) and comparison with its human homologue. Matrix Biol (1999) 0.80
Cell kinetic analysis of mixed populations using three-color fluorescence flow cytometry. Cytometry (1991) 0.80
Use of fluorescence in situ hybridization to determine the relationship between chromosome aberrations and cell survival in eight human fibroblast strains. Int J Radiat Biol (1995) 0.80